Oppenheimer & CO Inc Intellia Therapeutics, Inc. Transaction History
Oppenheimer & CO Inc
- $6.52 Billion
- Q4 2024
A detailed history of Oppenheimer & CO Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Oppenheimer & CO Inc holds 17,885 shares of NTLA stock, worth $187,971. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,885Holding current value
$187,971% of portfolio
0.0%Shares
6 transactions
Others Institutions Holding NTLA
# of Institutions
319Shares Held
91MCall Options Held
442KPut Options Held
880K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl12.5MShares$132 Million1.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.63MShares$101 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$101 Million0.0% of portfolio
-
State Street Corp Boston, MA5.14MShares$54.1 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.95MShares$52 Million3.75% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $799M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...